Inflammatory carcinoma of the breast

Also known as: Inflammatory Breast Cancer / Inflammatory Breast Cancer (IBC) / Mastitis carcinomatosa / Inflammatory Breast Neoplasms / Breast carcinoma inflammatory

DrugDrug NameDrug Description
DB06366PertuzumabPertuzumab is a recombinant humanized monoclonal antibody that targets the extracellular dimerization domain (Subdomain II) of the human epidermal growth factor receptor 2 protein (HER2). It consists of two heavy chains and two lights chains that have 448 and 214 residues respectively. FDA approved June 8, 2012.
DrugDrug NamePhaseStatusCount
DB11059Carboxymethylcellulose0Active Not Recruiting1
DB00112Bevacizumab1Recruiting1
DB00958Carboplatin1Completed1
DB00531Cyclophosphamide1Recruiting1
DB01248Docetaxel1Recruiting1
DB00445Epirubicin1Recruiting1
DB00544Fluorouracil1Recruiting1
DB01229Paclitaxel1Completed1
DB00072Trastuzumab1Completed1
DB00072Trastuzumab1Recruiting1
DB01229Paclitaxel1 / 2Terminated1
DB06176Romidepsin1 / 2Terminated1
DB00041Aldesleukin2Completed1
DB01008Busulfan2Completed1
DB00958Carboplatin2Completed1
DB00958Carboplatin2Recruiting2
DB00493Cefotaxime2Active Not Recruiting1
DB00493Cefotaxime2Completed1
DB00515Cisplatin2Completed1
DB00531Cyclophosphamide2Active Not Recruiting1
DB00531Cyclophosphamide2Completed2
DB00531Cyclophosphamide2Recruiting3
DB06643Denosumab2Recruiting1
DB00997Doxorubicin2Active Not Recruiting1
DB00997Doxorubicin2Completed2
DB00997Doxorubicin2Recruiting2
DB00445Epirubicin2Recruiting1
DB08871Eribulin2Recruiting1
DB00099Filgrastim2Active Not Recruiting1
DB00099Filgrastim2Completed1
DB01042Melphalan2Completed1
DB01229Paclitaxel2Active Not Recruiting1
DB01229Paclitaxel2Completed2
DB01229Paclitaxel2Recruiting3
DB09037Pembrolizumab2Recruiting1
DB06366Pertuzumab2Recruiting1
DB08877Ruxolitinib2Recruiting1
DB00020Sargramostim2Completed2
DB01268Sunitinib2Active Not Recruiting1
DB00675Tamoxifen2Completed1
DB04572Thiotepa2Completed1
DB04960Tipifarnib2Completed1
DB00072Trastuzumab2Completed1
DB00072Trastuzumab2Recruiting1
DB01157Trimetrexate2Completed1
DB00112Bevacizumab2 / 3Completed1
DB00958Carboplatin2 / 3Completed1
DB00515Cisplatin2 / 3Completed1
DB00515Cisplatin2 / 3Recruiting1
DB00997Doxorubicin2 / 3Completed1
DB01259Lapatinib2 / 3Completed1
DB01006Letrozole2 / 3Recruiting1
DB01229Paclitaxel2 / 3Completed1
DB01229Paclitaxel2 / 3Recruiting1
DB00958Carboplatin3Completed1
DB00493Cefotaxime3Terminated1
DB00515Cisplatin3Recruiting1
DB00531Cyclophosphamide3Completed2
DB00531Cyclophosphamide3Recruiting1
DB00531Cyclophosphamide3Terminated1
DB00380Dexrazoxane3Terminated1
DB01248Docetaxel3Completed1
DB00997Doxorubicin3Completed1
DB00997Doxorubicin3Terminated1
DB00445Epirubicin3Completed2
DB00445Epirubicin3Recruiting1
DB08917Ferric Carboxymaltose3Completed1
DB00544Fluorouracil3Recruiting1
DB01229Paclitaxel3Active Not Recruiting1
DB01229Paclitaxel3Completed1
DB01229Paclitaxel3Recruiting1
DB01229Paclitaxel3Terminated1
DB06366Pertuzumab3Completed1
DB00675Tamoxifen3Terminated1
DB00072Trastuzumab3Completed1
DB00072Trastuzumab3Terminated1
DB01157Trimetrexate3Terminated1